Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 8Recurrence 7Neoplasm Metastasis 7Prostatic Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Non-Hodgkin 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Basal Cell 5Multiple Myeloma 4Lymphoma, Follicular 4Hematologic Neoplasms 4Advanced Solid Tumors 4Wilms Tumor 3Solid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neuroblastoma 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Lymphoma × Itraconazole × Clear all
NCT05602597 2024-03-06

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Hutchmed

Phase 1 Completed
59 enrolled
Lymphoid

Lymphoma, Recurrence

NCT05720767 2023-03-01

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

Hutchmed

Phase 1 Completed
28 enrolled
Lymphoid

Lymphoma, Recurrence

NCT02259010 2019-09-20

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Takeda

Phase 1 Completed
24 enrolled 26 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡